Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines

ABSTRACT:

Introduction

A second generation HPV vaccine has been developed for the prevention of anogenital cancers and precancerous lesions of the cervix, vulva, vagina, anus and of genital warts due to nine HPV types. We estimated the annual burden of these diseases attributable to the nine HPV types compared to HPV types from first generation vaccines in women and men in Europe.

Material and methods

Incidence rates from the IARC database, cancer registries, the literature and Eurostat population data were used. The burden attributable to the HPV types targeted by both vaccines was estimated by applying the relative contribution of the respective HPV types from epidemiological studies.

Results

In 2013, the number of new anogenital HPV-attributable cancers was 44,480 with

SUBMITTER: Hartwig S 

PROVIDER: S-EPMC5886848 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature